Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 14, Status: Authorised
Committee for Orphan Medicinal Products (COMP): 6-8 October 2026, European Medicines Agency, Amsterdam, the Netherlands, from 6 October 2026 to 8 October 2026
Agenda of the COMP Meeting 6-8 October 2026
Product Management Service (PMS) - Frequently Asked Questions (FAQs)
Ninth European Medicines Agency (EMA) and EFPIA bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 16 September 2026, 10:30 (CEST) to 16 September 2026, 12:30 (CEST)
Records of data processing activity relating to the management and processing of documents related to absences due to illness or accident and consultations with the occupational health physicians
European platform for regulatory science research meeting: October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 October 2026, 09:00 (CEST) to 22 October 2026, 17:00 (CEST)
Developing cancer medicines for children
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes